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Introduction
  In order for agricultural biotechnology (agri-biotech) [FN1] to play a larger role in the development of
sustainable agricultural systems, [FN2] intellectual property (IP) rights management must be addressed.
These issues are not limited to developing countries. With increased globalization, the management of agri-
biotech IP rights affects both developing and industrialized countries. In industrialized countries, for
example, IP rights risk management entails protection of inventions via strong patent portfolios. For
developing countries, IP rights risk management includes the acquisition of rights requisite for the use of
inventions essential to the basic welfare of the population. Strategies are needed to bridge these disparate IP
management paradigms to facilitate the successful transfer of the agri-biotech from an industrialized
country source to a developing country recipient.
  *48 This paper examines IP management linked to agri-biotech products. Further, this paper examines
Golden Rice, a genetically engineered rice strain that accumulates beta-carotene (i.e., pro-vitamin A) in the
endosperm tissue of grain, as a case study for IP management, with emphasis on the international
movement of agri-biotech from industrialized to developing countries. [FN3] Topics discussed include: the
application of agri-biotech to international development; the challenge of transferring this technology from
industrialized to developing countries; a method for evaluating the IP constraints impinging on the
deployment of Golden Rice; industrialized/developing country perspectives vis--vis IP rights management;
six shorter-term options for the management of IP connected to Golden Rice; and a longer-term proposed
path to sustainable transfers of agri-biotech products.
Background
  Six factors continue to pressure global agricultural production capacity: a rapidly expanding global
population; an increasing demand for water resources; the depletion of quality water resources; the decline
in arable land resources; pressure on crop production by diseases, pests and unfavorable climatic
conditions; and the ever-increasing demand for quality food products. In developing countries the situation
is especially critical. [FN4]
  Historically, the "Green Revolution" [FN5] of the 1960s and 1970s effectively addressed pressing food
concerns of that time. This was *49 accomplished primarily via conventional plant breeding and improved
crop management practices. Of particular importance to the Green Revolution were the activities of the
Consultative Group on International Agricultural Research (CGIAR). [FN6] The CGIAR has traditionally
been a primary source/conduit of agricultural science and technology for the developing world. [FN7]
However, since many agri-biotech discoveries and applications are protected by their industrialized country
owners, it is difficult for CGIAR to legally distribute these to its developing world clients. Indeed, CGIAR
has only recently begun major agri-biotech research. [FN8]
  Agri-biotech has considerable potential for contributing to sustainable agricultural systems in developing
countries. [FN9] Therefore, it is seen as an innovative approach to circumvent starvation, i.e., a "Second
Green Revolution." [FN10] However, unlike the agronomic approach of the "First Green Revolution," agri-
biotech is very expensive. Millions of scientific research hours and dollars go into the production and
release of agri-biotech products. Therefore, organizations [FN11] that produce and own agri-biotech
products have surrounded their discoveries with IP protection (patent portfolios).
  *50 Increasingly, agri-biotech is owned by private sector corporations.  [FN12] The proportion of global
agri-biotech research and development expenditures by the private sector has grown from approximately
65% in 1994- 1995 to 80-85% in 1999. [FN13] Hence, with so many agri-biotech products subject to IP
protection, their commercial distribution to the developing world poses significant challenges. Corporations
with substantial agri-biotech property portfolios are understandably reluctant to donate these products to
developing countries which frequently lack enforceable IP protection and management capability.
Corporations justifiably fear that such humanitarian acts might establish, or at least strengthen a competitor.
  Developing countries would likely benefit from cutting-edge agri-biotech applications, most of which are
the property of industrialized country-based corporations. However, many of these same developing
countries are currently incapable of protecting or managing such property rights. Therefore, to develop and
maintain international agri-biotech transfer, industrialized and developing countries need to cooperatively
implement manageable systems of IP protection. As a critical component of this strategy, developing
countries need to implement appropriate IP policies and effective enforcement procedures.
Golden Rice
  Genetic engineering of crops has predominantly been in the production side  (e.g., herbicide tolerance,
insect resistance, virus resistance, fungi resistance), and less on the consumer side. [FN14] These first
generation transgenic crops, targeted more towards the farmer, [FN15] *51 represent attempts to reduce
input costs. However, second generation transgenic crops embody "value-added innovations." [FN16]
Golden Rice, as a second generation transgenic, is a pioneering step in the use of agri-biotech to produce a
significant impact at the consumer level, more specifically in developing countries. [FN17]
  In Golden Rice, the successful engineering of the carotenoid biosynthetic pathway (i.e., genes) in the rice
endosperm, with the subsequent expression of pro-vitamin A (i.e., beta-carotene), represents a remarkable
technological accomplishment. Specifically, this is due to the utter complexity of the carotenogenic
pathway, as well as the interrelated nature of plant metabolic systems. [FN18] This technical and scientific
complexity clearly indicates the IP/technical property (TP) [FN19] complexity of Golden Rice, which, in
turn, makes its transfer to the developing world such a challenge.
  Golden Rice has significant potential for the alleviation of chronic vitamin A deficiency (VAD)
throughout the developing world. [FN20] VAD is a serious public health problem, [FN21] with worldwide
estimates *52 of 100 to 200 million children affected. [FN22] In 1989, up to 1.2 million deaths of
preschoolers were attributed to VAD. [FN23] Five hundred thousand children are permanently blinded
every year due to xerophthalmia (severe VAD). [FN24] These children die at nine times the rate of healthy
children. [FN25] Between one and three million children die of infections every year, preventable if the
children had not been deficient in vitamin A. [FN26]
  Golden Rice represents the vanguard for a new class of agri-biotech products, and a model case study for
the effective, efficient, and equitable distribution of an agri-biotech product from industrialized country
sources to developing countries where such products are most needed. Unresolved IP/TP rights constraints
present the risk of complicating international deployment of Golden Rice. This truly is a human dilemma in
that restrictions on the distribution of beneficially appropriate, value-added, genetically engineered crops to
developing countries may affect the welfare of millions of lives, and, in the case of Golden Rice, millions
of children. For this reason, management of IP and TP issues associated with Golden Rice have potentially
far-reaching ramifications.
Methodology
  Pragmatic management of the international transfer of IP/TP rights associated with an agri-biotech
product (e.g., Golden Rice), begins with a systematic product clearance (PC). [FN27] This is a para-legal
document *53 produced in large measure by scientists who clearly understand the inherent technological
complexities of the product. The PC involves a detailed listing and analysis of all aspects of the agri-
biotech product. The PC is a detailed dissection, referred to in this paper as a "product deconstruction," into
the product's essential components. The PC is based on, and developed from, a series of questions such as:
what are the methods and procedures that went (will go) into producing the agri-biotech product; what are
its principal components; what are the essential ingredients that constitute each principal component; what
are the IP/TP rights that may be attached to each component and its ingredients; and who seems to own the
IP/TP rights of each component and each of its ingredients?
  Ideally, the PC describes and analyzes every essential aspect of the product. It must be as comprehensive
as economically possible. Product deconstruction can take place either when the product is in the planning
stage, when the research and product development is underway, or when the agri-biotech product, such as
Golden Rice, is ready for distribution. Further, once the product is in the stream of commerce, it is prudent
to produce an annual PC update because of the changing IP/TP rights landscape.
  *54 Generally, it is in any organization's strategic best interest to conduct a product deconstruction at the
earliest possible phase in product development. When alternatives exist, this process can help research
scientists focus only on those items where IP is most readily available. In some cases, the thrust of the
scientific research may be to invent around a competitor's IP position. Producing a timely, proactive PC is a
wise resource expenditure. It permits an early assessment of the IP landscape and allows management
decisions to be made well in advance regarding which components, technologies, and processes are best to
incorporate into the product under development, in order to avoid using those which are not owned or
cannot be readily licensed.
  A patent attorney can then draft a freedom to operate (FTO) [FN28] opinion. This is written on the basis
of the para-legal PC, the attorney's thorough search of various patent databases, a review of the applicable
patent claims, an understanding of the appropriate laws, and an analysis of all the pertinent documents such
as Material Transfer Agreements (MTAs) [FN29] that might impact the product being developed. Finally,
with all of this in place, the patent attorney renders an FTO opinion.
  Such an FTO opinion is ideally performed as early as economically feasible in the product development
cycle as a pre-emptive "IP/TP rights hygiene" review. However, because of the significant resource *55
requirement for such a FTO review, every agri-biotech R&D organization will be limited in the number of
FTO opinions that it is willing to initiate. Further, because nearly all statutory protection is based on
national law rather than international law, a separate FTO review is required for each country where a
product will be made, used, imported, or sold. In addition, because new patents are continually issuing
while others are expiring, the IP landscape is in continual flux. An FTO opinion is therefore a snapshot, and
thus, is a risk management opinion regarding a particular product at a particular time for a particular
country.
  In a product deconstruction, it is vitally important to distinguish between IP rights and TP rights. This
cannot be overemphasized. All IP issues need to be searched and all TP concerns must also be accurately
identified and assessed. The sources of TP from other parties must be clearly documented to ensure that
such TP has been obtained under an appropriate MTA. It is similarly important to assure that the source of
the TP had a legitimate right to distribute that TP. A review of the MTAs will clarify the legitimate
ownership of such TP as was used to produce the new agri-biotech product and will lay the groundwork for
knowing if the developing country scientists will have commercial use and/or distribution rights.
  As a part of IP/TP rights analysis attached to a new agri-biotech product, germplasm rights must be
thoroughly investigated. This entails reviewing the source of all germplasm that is used to produce the new
product. It must be determined if germplasm is protected, for example, by plant variety protection, a plant
patent, or a utility patent. [FN30] The germplasm variety, inbred, or breeding population used to develop a
transgenic product represents the foundation of that *56 product. A detailed tracing of plant pedigrees with
a determination of any rights or licenses attached to the germplasm (e.g., "bag tags"), [FN31] that impose
any limitation on the use of and/or distribution of seeds and their progeny, must be duly carried out far in
advance of product introduction. This analysis of the source of all germplasm must be included in the FTO
opinion.
  A product deconstruction of Golden Rice is presented in the following section.
Summary of Analyses
  The overall product deconstruction of Golden Rice [FN32] tentatively identified 15 TP components and
70 patents (with 31 assignees) [FN33] of potential relevance. A great deal of this complexity stemmed from
Golden Rice being a multi-transformant. Genes (enzymes/enzymatic activities/steps) required to catalyze
four steps in the carotenogenic biosynthetic pathway were successfully engineered into rice seed
endosperm. [FN34] Each of these, in turn, was assembled into a genetic transformation construct, complete
with plant transcription promoter and termination sequences, as well as appropriate selectable markers. In
the product deconstruction of Golden Rice, four major components were examined:
  1. Plant/seed source, the rice race japonica (TP309), which is a tropical variety adapted to Taiwan; [FN35]
  *57 2. Gene constructs, e.g., cloning vectors (pBluescriptKS);plant transformation vectors (pBin19hpc,
pZPsC, pZLcyH);
  3. Transformation (Agrobacterium-mediated), tissue culture (scutella culture), plantlet regeneration (NB
medium), as well as other techniques; and
  4. DNA amplification, the polymerase chain reaction (PCR), and the enzyme that catalyzes this reaction
(Thermus aquaticus "Taq" polymerase).
  In turn, each of these major component categories was further dissected to yield deeper layers of
complexity in the product. For example, the plant transformation vector pBin19hpc is a complex construct,
with numerous subcomponents and processes integral to its generation, among these: the plant gene
promoter CaMV35S; the seed endosperm specific gene promoter Gt1; the selectable marker nptII
(kanamycin resistance); the pea Rubisco small subunit transit peptide (DNA); the selectable marker aphIV
(hygromycin resistance); the carotenoid biosynthetic gene psy (phytoene synthase); the carotenoid
biosynthetic gene crtI (phytoene desaturase); Agrobacterium-mediated transformation; and co-
transformation technology. Each of these components might have IP and/or TP rights attached to it,
potentially affecting the eventual FTO opinion. IP and TP issues potentially constraining the distribution of
Golden Rice will vary on a country-to-country basis.
  The product deconstruction of Golden Rice, as well as any similarly complex product, is additionally
challenging due to the added factor of uncertainty. Four types of uncertainty are considered here:
  (1) Complexity of assignees on patents. In the case of Golden Rice, thirty-one were tentatively identified.
[FN36] However, it is important to note that these are the original assignees as listed on the patent cover
pages. Because the corporate world is in a constant state of change, determining precisely which entity has
the right to grant licenses for a particular component or process is not always straightforward. Indeed, as
companies re-structure, sell/assign patents, or grant licenses, with or without the right to sub-license, the
degree of uncertainty increases.
  *58 (2) Absence of MTAs for TP. If a MTA for a specific TP component is not available, this does not
mean that distribution of that component is without restrictions. On the contrary, such absence of a MTA
probably signals the need for greater caution and deeper investigation due to the added uncertainty which
this produces. Although most agri-biotech research facilities in industrialized countries have functioning
technology transfer offices, it is not uncommon for researchers to bypass the procedures set up by these
offices. For example, scientists, particularly those at public sector research facilities, have long exchanged
TP components (e.g., plasmid constructs, gene promoters, antibodies) very casually. Therefore, the absence
of a MTA for a particular TP component should be heeded as a warning sign and not some sort of
"fortuitous convenience."
  (3) Import/export issues. The potential impact of international movement  (import/export) of Golden Rice
adds an additional layer of complexity to the international IP landscape. For example, if a product is
produced outside the U.S. using an unlicensed U.S. patented process, U.S. law prohibits the importation of
such products back into the U.S. [FN37] Similar provisions are incorporated into the language of the Trade-
Related Aspects in Intellectual Property Property Rights agreement. [FN38] As the IP landscape evolves,
worldwide IP harmonization proceeds, and the globalization of biotechnology extends more and more to
developing countries, this situation will require continual and careful attention. [FN39]
  (4) Static (narrow time-frame) vs. dynamic (broad time-frame) PC analysis. There is uncertainty and
attendant risk associated with static versus dynamic PC analysis. Binenbaum et al. have observed that since
most of the IP present in Golden Rice is not protected in the majority of regions where it is to be
distributed, the PC analysis (to the *59 extent performed for Golden Rice) is largely not applicable. [FN40]
In a static time frame, this is a correct and coherent observation. However, when reconsidered within the
context of the dynamic nature of the international IP landscape, the uncertainty of future changes and
developments, whether it be five, ten, or twenty years ahead, predominates. This persistent level of
uncertainty, therefore, gives good reason for a dynamic, comprehensive, and global PC analysis. Hence,
having better knowledge of the global IP landscape facilitates informed risk assessment (i.e., a greater
number of potentialities can be anticipated). The two paradigms (static and dynamic) are not mutually
exclusive, rather, they are two legitimate viewpoints. The static paradigm is an analysis of a "snapshot,"
and the dynamic paradigm relates more to the complex and fluid realities of international development and
the harmonization of global IP rights systems. Related to this is the viewpoint that the entities which
produce/own the most advanced agri-biotech applications released in industrialized countries will not seek
IP rights protection on these products in developing countries. As a result, due to this lack of strong IP
rights protection, developing countries would have a distinct advantage to be able to access (i.e., "pirate")
these new products. Indeed, in the short term this may be true. However, a longer-term perspective suggests
that such an approach would bring developing countries the greater risk of only obtaining second-tier
products, rather than those that are truly cutting-edge. Unfortunately, this limitation would principally
impact the developing countries that can benefit most from products such as Golden Rice.
Options
  The preliminary PC analysis, as summarized in this paper, was conducted to better understand the current
IP/TP rights situation so that options and alternative future strategies can be discussed and developed.
Resource-poor farmers and rice consumers in developing *60 countries where rice is a staple are intended
to be the ultimate beneficiaries of the deployment of Golden Rice. This desired end result, of providing
farmers and consumers with a superior product, is the same regardless of the type of donor/recipient entities
(i.e., private corporate, public university, national agricultural research center, philanthropic) that may be
involved. The means and acceptable level of risk will likely vary depending on the nature of these
organizations.
  Hence, as a risk management tool, this study can serve as a template for an organization's assessment and
management of risk (i.e., the degree of risk that it is willing to assume). What we present here, therefore, is
a framework within which an IP/TP risk management course of action can be mapped out, taking advantage
of a maximum amount of data that can realistically be assembled, analyzed, and organized. Furthermore,
since numerous types of organizations are potentially involved and the term "developing country" is a
broad categorization for many different countries, each with unique circumstances, a blanket
recommendation is not possible.
  Capacity building in IP/TP risk assessment and management is also of critical importance. [FN41] In that
respect, the authors present six alternative options regarding the IP/TP risk management of Golden Rice.
[FN42] Then it is hoped that, as full partners, developing and industrialized countries can proceed with
deliberation and the decision to find the most appropriate process for the development, distribution, and
production of agri-biotech products such as Golden Rice.
  *61 Option 1: Invent around the current patents. This is an intensive science and research-based approach,
which entails developing and inventing alternative ways to "regenerate" Golden Rice. This could involve
using alternative biosynthetic genes to engineer rice that accumulates carotenoids in the seed endosperm,
hence an entirely new invention. For example, genes from plant sources might replace the bacterial genes,
which had been used to originally generate Golden Rice. However, because it attempts to reduce the
reliance on patents owned by others, this option may, relatively speaking, be too time consuming or costly,
and, for scientific reasons, may be extremely laborious or not even feasible.
  Option 2: Re-design the constructs. This is a product-development based approach and involves the re-
design and re-engineering of the molecular constructs to purposely avoid certain TP and/or IP constraints,
depending on the language found in relevant patents or licenses. Redesigning the constructs might involve
reassembling the various molecular pieces found in Golden Rice, with possible substitutions (e.g., different
markers and/or promoters instead of attempting to obtain these as "pre-assembled" packages). This
approach may be quite effective, but, at best, science is not easily predictable and, at worst, such an
approach will require considerable time (possibly three to five years).
  Option 3: Approach all current IP/TP owners with a request that they relinquish their proprietary claims.
[FN43] This is a humanitarian approach focused on public perception. Public or private statements of rights
abandonment by the certified owners/assignees for each IP/TP right would eliminate all FTO issues
attached to commercial activities with Golden Rice. This approach, of course, would greatly simplify
licensing negotiations. However, a royalty-free license might still be required due to various
liability/indemnity reasons. Further, such an *62 approach might work on high profile products like Golden
Rice, but might not provide full freedom to operate for all new agri-biotech products.
  Option 4: Ignore all IP and TP rights claims and just produce and distribute the agri-biotech product. This
is a short-term perspective with the lowest initial cost. However, longer-term difficulties are likely to ensue
if this option is followed. For example, lawsuits, delays of product distribution, limitations on importation
capabilities, and poor relations with IP/TP owners are some of the unpleasant possibilities that might flow
from this option.
  Option 5: Seek licenses from all of the IP and TP rights owners. This is the licensing approach. It would
require the acquisition of an appropriate license for each individual IP/TP right connected to Golden Rice.
The nature of the license negotiated would be determined by the needs of the potential licensee, as well as
by what the licensee and licensor mutually determine to be required. This is the safest route to distribution,
and ensures good, long-term relationships with the IP/TP rights holders. However, this option is complex,
costly, and potentially very time consuming. Furthermore, given the relatively limited legal and
governmental infrastructure in many developing countries, the owners of the IP/TP rights may be reluctant
to consummate such licenses until the recipients exhibit additional IP rights management capacity.
  Option 6: A mix of all of the options 1 to 5. This represents a pragmatic, realistic approach to obtaining
full FTO for Golden Rice. Due to the flexibility imparted by taking advantage of the numerous available
options, this is the most effective route for the distribution of Golden Rice. However, it still requires that
both the recipients of Golden Rice and the donors understand and recognize the issues that are involved.
*63 Discussion
Sustainable, Equitable, and International Agri-biotech Transfers: Managing
Risks and Maximizing Opportunities
  Despite current disagreements over the appropriateness of various proposed IP regimens and
inconsistencies in enforcement of IP laws throughout the developing world, the inexorable movement
towards global harmonization of IP rights systems appears highly likely. [FN44] This trend is linked to the
continuing expansion of the global economy. [FN45] As the legal norms for IP rights protection become
progressively more consistent at the international level (i.e., the international deployment of IP systems
similar to those that have proven to be successful in industrialized countries) trans-national corporations are
likely to increase operations in developing countries. [FN46] Worldwide recognition of, and adherence to,
IP rights harmonization should facilitate the participation of many countries as full partners in the global
economy. [FN47] For developing countries, agricultural improvement is a top priority.
  When considering the global harmonization of IP rights protection, certain realities must be appreciated.
Developing countries will change, but it is critical to recognize that such change is gradual, and proceeds
*64 stepwise. In this context, a "three-stage model" of IP rights evolution in developing countries is useful:
[FN48]
  1. The first stage is in those countries with the lowest level of economic development. In such countries,
IP rights protection is not an issue because the economic and technological infrastructure is below the basic
requirement needed for utilization of technological advances.
  2. The second stage is in those countries that can utilize advanced technologies, but the economic level of
development, or the domestic supply of capital, is still low. In these circumstances, technology piracy
routinely occurs.
  3. The third stage is in those countries where public and private entities can generate world-class
inventions. Here, IP rights protection becomes essential in order to credibly and productively participate in
the international economic community, with reciprocal recognition and enforcement of IP rights.
  Coupled with the global harmonization of IP rights is the inexorable international spread of biotechnology
into agricultural systems. [FN49] The global planting of transgenic crops continues to increase. In
industrial countries where the total transgenic acreage is currently concentrated, the rate of deployment of
transgenic crops currently appears to be leveling off. However, in developing countries, the planting of
transgenic crops is increasing significantly. [FN50] In both industrialized and developing countries where
transgenic crops have, until recently, been primarily agronomic (crop-protection) based, value-added
products with broad application such as Golden Rice are on the horizon. [FN51]
  *65 Due to the differing perspectives and circumstances of industrialized and developing countries,
establishing a foundation for fair and equitable negotiations vis--vis IP rights is not simple. Many
developing countries may not consider the legal recognition of foreign patents to be important. [FN52]
When negotiating license terms, developing countries are usually at a disadvantage because key personnel
are inadequately trained [FN53] and most developing countries have an insufficient number of licensing
officials and IP managers. [FN54] Therefore, in such developing countries, since agriculture is considered
integral to national sovereignty, piracy of agri-biotech is more likely to be considered justifiable. [FN55]
The unfortunate legacy of colonialism complicates the situation even more. [FN56] From the industrialized
country perspective, investors view the IP portfolio of a company as an absolutely essential component.
[FN57] The system of IP rights protection of a potential partner influences technology transfer and
investment decisions. [FN58] Therefore, industrialized countries firmly believe that a healthy patent system
encourages invention/investment in a sustainable fashion. [FN59] Notwithstanding the different viewpoints
between developing and industrialized countries, improved IP rights harmonization appears to be integral
to the economic development of all countries. [FN60] Hence, if IP issues are adequately addressed, *66
globalization presents opportunities to move agri-biotech internationally, thereby fostering the
technological and legal infrastructure conducive to domestic R&D activities (that is, "home-grown product
development") within developing countries.
  Within the context of these disparate positions, momentum for constructive change is essential.
Industrialized countries need to understand the evolutionary process of IP protection in developing
countries and to provide incentives to facilitate accelerated progression from Stage 1 (i.e., minimal
technology infrastructure) to Stage 3 (i.e., technology infrastructure with IP protection). [FN61]
Correspondingly, developing countries need to fully recognize the necessity of stable and enforceable IP
systems, which will support the sustainable movement of advanced agri-biotech into their countries. Under
the best of circumstances, this is a win-win scenario. [FN62] The long-term benefits to the technology
providers (most likely industrialized countries) include: protection of IP portfolios; protection and
expansion of commercial markets, while providing technology to those who need it most; improved public
perception of trans-national corporations; and new, sustainable partnerships. The long-term benefits to
technology recipients (mostly developing countries) include: increased agricultural outputs; improved
agricultural products (e.g., Golden Rice); opening of export markets; access to "hands-on" knowledge and
skill of practitioners of the art; legal access to patented technologies at a more fundamental level; [FN63]
fostering of a national infrastructure for *67 sustainable technology development; fostering of a legal
infrastructure; [FN64] and new, sustainable partnerships.
  Golden Rice represents a specific case study/model system of an agri-biotech product that can be
transferred to the developing world. The genetic engineering of value-added nutritional quality into Golden
Rice is a turning point both scientifically and in terms of international technology transfer. Scientifically,
the engineering of plant (in this case rice) metabolism to enhance accumulation of carotene is a complex
and pioneering advance. To transfer this promising technology from the industrialized sources who own it
to the developing countries of the world, where it is most needed, is equally complex. This paper proposes
six short-term strategies for management of IP risk potentially associated with the international movement
of Golden Rice. However, over the longer term, increased international harmonization of IP laws and
management might serve to ameliorate many of these risks, and hence facilitate the sustained transfer of
Golden Rice as well as future advances in agri-biotech.
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